How do I discuss with a Spanish-speaking sickle cell patient what she legally has to disclose to her employer and what she can keep private?

The patient with sickle cell disease who is afraid to tell her employer is navigating a real asymmetry: she needs accommodation but fears that asking for it will mark her as unreliable before she has had the chance to prove otherwise. The conversation starts by separating what the law says from what her employer actually needs to know. Under the Americans with Disabilities Act, she does not have to disclose a diagnosis to request accommodation. She can say: “Tengo una condición médica crónica que de vez en cuando requiere tiempo para citas médicas y, en casos raros, para manejar una crisis de salud.” That sentence is legally sufficient to open the accommodation conversation without naming sickle cell disease. What the employer is entitled to know is what she needs, not why she needs it. The accommodation she is most likely to need is intermittent leave — the ability to call in or leave early on a crisis day without it counting against her attendance record in the standard way. That is a recognized reasonable accommodation under the ADA. She does not have to ask for it at hire. She can ask at any point. The phrase for requesting it: “Quiero hablar con Recursos Humanos sobre una acomodación razonable para una condición médica.” After twelve months of employment and 1,250 hours worked, she may also qualify for FMLA, which provides up to twelve weeks of protected leave per year for serious health conditions — including sickle cell crises. The nurse’s role is not to advise her on employment law; it is to tell her that the all-or-nothing frame she is working from — either full disclosure or complete silence — is not the only option, and that there is a middle path that does not require her to say the words ‘enfermedad de células falciformes’ to anyone at work.

How do I explain to a Spanish-speaking patient why the hydroxyurea he takes for polycythemia vera is not the same as cancer chemotherapy?

The patient who heard from a leukemia survivor that hydroxyurea is chemotherapy is not wrong about the fact — hydroxyurea is used in cancer treatment. What is wrong is the inference that his experience on the medication will resemble what the leukemia patient experienced. The conversation has to distinguish three things: the disease, the reason the medication is used, and the dose. “La policitemia vera y la leucemia que tuvo su vecino son enfermedades de la sangre, pero son muy diferentes en lo que hacen y en lo que necesitan. La leucemia es un cáncer — las células cancerosas crecen de manera descontrolada y el tratamiento busca destruirlas, lo que requiere dosis altas y causa efectos secundarios significativos. La policitemia vera no es un cáncer en ese sentido — es una condición en la que la médula ósea produce demasiados glóbulos rojos, y la sangre se vuelve más espesa de lo que debería. La hidroxiurea en la policitemia vera se usa en dosis mucho más bajas — una décima parte o menos de lo que se usa en leucemia — para decirle a la médula que produzca menos. El objetivo es bajar su hematocrito a un nivel seguro, no destruir células cancerosas. Por eso los efectos secundarios que tuvo su vecino — las llagas, el adelgazamiento, la fatiga intensa — generalmente no ocurren a las dosis que usted estaba tomando.” The concrete risk of stopping: “Cuando la policitemia vera no está controlada, el riesgo principal es que la sangre espesa forme un coágulo en el lugar equivocado — en el corazón, en el cerebro, en una vena profunda de la pierna. Su hematocrito hoy es 54 por ciento. Cuando estaba tomando la hidroxiurea era 43. Esa diferencia equivale a una sangre significativamente más viscosa que tiene más probabilidad de coagular. El mayor riesgo de la policitemia vera no controlada no es que le crezca un tumor — es un infarto o un derrame cerebral que viene sin previo aviso.”

How do I find out that a Spanish-speaking hemophilia patient has been reducing his infusion frequency because of cost without directly asking about his finances?

The hemophilia patient who is rationing his factor VIII concentrate does not present differently from a patient who is fully adherent. He says ‘todo está bien.’ He has not had a dramatic joint bleed. The silent bleeds that accumulate into arthropathy over years are not events he can report — he does not feel them in the way he would feel an acute hemarthrosis. The first question is schedule-specific, not outcome-specific: “¿Cómo va el horario de las infusiones en casa — tres veces por semana como siempre, o ha habido alguna semana donde salió diferente?” The phrase ‘alguna semana donde salió diferente’ normalizes the variation before the patient has to confess it as an error. If he hedges — ‘más o menos’ or ‘casi siempre’ — the follow-up is concrete: “¿Cuántas veces por semana ha sido en el último mes — tres o dos?” Once he confirms two, the nurse asks about the reason without framing it as a failure: “Cuando el horario cambia, muchas veces hay algo práctico detrás — un cambio en el seguro, en el copago, en la farmacia. ¿Algo cambió en la cobertura cuando empezó el trabajo nuevo?” This question names the most common structural reason without accusing the patient of anything. The patient who says ‘sí, el copago es diferente ahora’ has just opened the conversation that connects him to the manufacturer patient assistance program and the hemophilia treatment center social worker — resources that most patients with newly acquired insurance problems do not know exist.

What are the Spanish terms for sickle cell disease, polycythemia vera, factor VIII, and hematology clinic nursing?

Sickle cell disease: “enfermedad de células falciformes,” “anemia falciforme” — patients say “el problema de la sangre,” “la anemia que tengo,” “la enfermedad de la sangre que nací con.” Vaso-occlusive crisis: “crisis de dolor,” “crisis vasooclusiva” — patients say “cuando me da el dolor,” “la crisis,” “cuando se me va la fuerza.” Hydroxyurea: “hidroxiurea” — patients say “la pastilla para la sangre,” “el medicamento del hemátolo go,” sometimes “el quimio” (if they have heard the oncology context). Fetal hemoglobin: “hemoglobina fetal” — patients say “el porcentaje que mejora,” rarely know this term. Polycythemia vera: “policitemia vera” — patients say “el problema de los glóbulos rojos,” “que tengo la sangre muy espesa,” “lo que encontraron en el análisis.” Hematocrit: “hematocrito” — patients say “el porcentaje de la sangre,” “el nivel del hematocrito.” Platelet count: “recuento de plaquetas,” “plaquetas” — patients say “las plaquetas,” “las que coagulan.” Thrombosis: “trombosis,” “coágulo” — patients say “un coágulo,” “que se tapó una vena.” Hemophilia: “hemofilia” — patients say “la hemofilia,” “el problema de la coagulación.” Factor VIII: “factor ocho,” “el factor VIII” — patients say “el factor,” “la infusión,” “lo que me pongo en casa.” Prophylaxis: “profilaxis,” “tratamiento preventivo” — patients say “la profilaxis,” “lo que hago para que no sangre.” Hemarthrosis: “hemartrosís,” “sangrado en la articulación” — patients say “cuando se hincha la rodilla,” “cuando me duele el tobillo.” Joint arthropathy: “artropatía hemofílica” — patients say “el daño de la articulación,” “que la rodilla ya no funciona como antes.” Co-pay: “copago” — patients say “lo que yo pago,” “mi parte.” Patient assistance program: “programa de asistencia al paciente,” “ayuda del fabricante” — patients often do not know this term at all.

Spanish for hematology clinic nurses: the patient with sickle cell disease who has not told her new employer about her pain crises, the patient with polycythemia vera who stopped his hydroxyurea because his neighbor told him it was chemotherapy, and the patient with hemophilia whose infusion schedule is slipping because the pharmacy co-pay increased when he aged off his parents’ insurance

2026-07-03 · ~27 min read · ClinicaLingo blog

Valentina Cruz was twenty-nine years old, a certified medical assistant four months into her first job with employer-sponsored health insurance, and she had come in for her routine hematology follow-up without mentioning the emergency department visit from three weeks prior. The nurse had reviewed the chart before entering the room. The ED note was there: bilateral lower back and hip pain, rated 9/10, vaso-occlusive crisis, IV hydromorphone 0.4 mg given three times over eighteen hours, discharged with a prescription for oral hydromorphone she had not yet filled at any pharmacy in the system. The attending note included a flag: “patient reports significant work stress around disclosure.” The nurse had written that note.

Valentina had called her supervisor from the ED parking lot at 11 PM. She had said she had a stomach virus. Her supervisor had told her to rest and not worry about the next two shifts. She had returned to work on the fourth day. Nobody had asked any follow-up questions. She had decided this meant the system had worked.

She had been on hydroxyurea 1000 mg daily for three years. Her fetal hemoglobin was 18% — up from 6% before treatment. Her annual vaso-occlusive crises had fallen from five per year to one. The crisis three weeks ago had been the first in fourteen months and had been triggered, she believed, by two consecutive twelve-hour shifts, a broken AC unit in the medical records room where she spent most of her day, and dehydration she had not noticed accumulating.

She arrived at the hematology clinic that afternoon saying “todo bien, lo de siempre.”

Three outpatient hematology clinic patterns that arrive without announcing themselves: Valentina, twenty-nine, a certified medical assistant with HbSS sickle cell disease who has been at her new job for four months without disclosing her condition, who called in sick from the ED parking lot and said “virus” during an admission for a vaso-occlusive crisis, and who has been working from an all-or-nothing frame — either full disclosure or complete silence — without knowing there is a third option; Heriberto Sánchez, seventy-one, a retired auto mechanic from Tucson with polycythemia vera who stopped his hydroxyurea ten weeks ago after his neighbor — a leukemia survivor who was on high-dose hydroxyurea during treatment and lost twenty pounds and grew leg ulcers — told him “eso es quimio, compadre, te come el cuerpo,” and who arrives with a hematocrit of 54% and a platelet count of 680,000; and Marco Herrera, twenty-six, a stockroom associate from San Antonio with severe hemophilia A who has had an annual bleed rate of zero for two consecutive years on prophylactic factor VIII three times weekly, who aged off his parents’ insurance at twenty-six and whose new plan’s specialty pharmacy co-pay is $240 per month, and who has been infusing twice weekly for six weeks to stretch his supply while arriving saying “todo está bien.”

The patient with sickle cell disease who has not told her new employer about her pain crises

The nurse began with the visit reason, not the ED chart. She asked how the last fourteen months had been.

Valentina: “Bien. Tuve una crisis hace como tres semanas, pero ya pasó. Antes tenía cinco al año — una en catorce meses está bien.”

“¿Cómo estuvo esa crisis — la manejaron en casa o tuvo que ir a alguna parte?”

A brief pause. “Terminé en urgencias. Dieciocho horas. Ya me dieron el alta.”

“¿Y cómo estuvo en el trabajo — pudo tomarse el tiempo sin problema?”

Valentina looked down at her hands. “Le dije a mi supervisora que tenía un virus. No sé cómo decirle lo que tengo sin que piense que soy poco confiable. Llevo cuatro meses. No quiero que piensen que contrataron a alguien que se enferma.”

The nurse wrote that down. Then she asked the question she had been thinking about since she read the ED note: “¿Alguien en el trabajo sabe que tiene la enfermedad de células falciformes?”

“Nadie. No lo poné en la solicitud de empleo. No sé si era obligatorio — pero si lo ponía, no me iban a contratar.”

“No era obligatorio. La ley no le exige que divulgue un diagnóstico médico para solicitar un empleo ni después de conseguirlo. Lo que sí puede hacer es pedir lo que se llama una acomodación razonable, que es cuando usted le dice al empleador que necesita un ajuste específico por una condición médica — sin tener que decirles el nombre de la condición. ¿Sabía eso?”

Valentina: “¿No tengo que decirles qué es?”

“No. Para pedir una acomodación, usted puede decir: ‘Tengo una condición médica crónica que de vez en cuando requiere tiempo para citas médicas y, en casos raros, para manejar una crisis de salud.’ Eso es suficiente. El empleador puede pedirle una carta de su médico que confirme que tiene una condición que requiere esa acomodación — pero no tienen derecho a saber el diagnóstico. La carta puede decir ‘condición hematológica crónica que puede requerir ausentismo intermitente.’”

Valentina was very still. “Creí que era todo o nada — o lo sabes todo o no sabes nada. No sabía que había algo en el medio.”

“Hay algo en el medio. La acomodación que probablemente necesita en su caso es la licencia intermitente — que si tiene una crisis y tiene que faltar uno o dos días, eso no cuente en su registro de ausentismo de la manera habitual. Eso es una acomodación reconocida bajo la Ley de Estadounidenses con Discapacidades. Usted no tiene que pedirla en el momento de la contratación. La puede pedir ahora, cuatro meses después. Lo que pasó hace tres semanas no tiene que quedar como un ‘virus’ en su expediente si usted decide que quiere protegerse hacia adelante.”

“¿Y si el jefe piensa que soy poco confiable de todas formas?”

“Ese es el miedo real, y lo entiendo. No puedo garantizarle cómo va a reaccionar su supervisor. Lo que sí puedo decirle es esto: en los últimos catorce meses, usted tuvo una crisis. Una. Con la acomodación pedida, esa crisis se convierte en un día de licencia protegida, no en una mentira que tiene que sostener. Sin la acomodación, la próxima crisis — si ocurre — es otro virus que tiene que inventarse. La decisión es suya. Pero quiero que la tome sabiendo que la opción existe.”

The nurse also told her about FMLA. After twelve months of employment and 1,250 hours worked, she would qualify for up to twelve weeks of protected leave per year for a serious health condition — including sickle cell crises. She was not there yet. But at month twelve, the option would exist.

She also went over trigger avoidance in the work environment: adequate hydration across a full shift, notifying her supervisor if the temperature in her workspace was extreme (she had the right to request a workspace adjustment for temperature under the same ADA framework), and pacing during physically demanding periods.

Valentina left with a draft letter — written in English, for her to review and decide whether to submit — from the hematologist, stating that she had a chronic hematologic condition requiring intermittent leave accommodation. She did not know yet whether she would use it. She had not known, before that visit, that the letter was something that could exist.

At her three-month follow-up, she told the nurse she had submitted the accommodation request. HR had processed it in two weeks. Her supervisor had not asked for any specifics. “Me dijo, ‘gracias por avisarme, aquí estamos para apoyarte.’ Solo eso. Me sorprendió.”

The patient with polycythemia vera who stopped his hydroxyurea because his neighbor told him it was chemotherapy

Heriberto Sánchez had been diagnosed with polycythemia vera fourteen months ago after a routine blood panel ordered by his PCP before a hernia repair came back with a hematocrit of 61% and a platelet count of 920,000. A JAK2 V617F mutation was confirmed. He was started on hydroxyurea 500 mg twice daily and therapeutic phlebotomy. At his four-month follow-up, his hematocrit had normalized to 43% and his platelets had fallen to 340,000. He had tolerated the medication well — mild fatigue in the first few weeks, no mouth sores, no leg ulcers, no significant changes in his bloodwork beyond the intended cytoreduction.

His neighbor Óscar had been treated for chronic myeloid leukemia five years ago. The treatment included hydroxyurea at high doses during the initial debulking phase, before he transitioned to a targeted agent. During those months, Óscar had lost eighteen pounds, developed painful mouth sores, and grown leg ulcers on both shins that had taken months to heal. He had told Heriberto all of this, repeatedly, over the years — the way you tell the story of a thing you survived and that marked you.

Ten weeks before this follow-up visit, Óscar had been sitting on Heriberto’s front porch and had asked what pill he was taking. Heriberto had said: “Hidroxiurea.”

Óscar had gone very still. “Compadre. Eso es lo mismo que me dieron a mí. Eso es quimio. Eso te come el cuerpo. Yo lo dejé en cuanto pude.”

Heriberto had stopped his hydroxyurea that evening.

He arrived for his scheduled follow-up. The nurse reviewed the labs drawn that morning: hematocrit 54%, platelet count 680,000. She knew from the medication adherence record that his last prescription refill had been picked up nine weeks ago — a thirty-day supply that should have run out in four weeks.

“¿Cómo ha estado, señor Sánchez? ¿Ha tenido algún problema con el medicamento — la hidroxiurea — desde la última vez que vino?”

Heriberto: “Pues, mire — la verdad que la dejé. Hace como diez semanas. Me enteré de algo y no me quedé tranquilo.”

“¿Qué fue lo que supo?”

He explained about Óscar. The leukemia. The months of hydroxyurea. The mouth sores and the leg ulcers and the weight loss. “Si es el mismo medicamento, no quiero terminar así. Prefiero no tomar nada.”

The nurse did not dismiss what Óscar had experienced. She started where Heriberto was.

“Lo que le pasó a su vecino fue real — esos efectos secundarios ocurren. Y tiene razón en que el medicamento es el mismo. Lo que es diferente es la razón por la que se usa y la dosis. Esas dos cosas cambian todo. ¿Me permite explicarle?”

“Sí, por favor.”

“La leucemia que tuvo su vecino es un cáncer — las células cancerosas crecen sin control y el tratamiento busca destruirlas. Para hacer eso, los médicos necesitan dosis altas del medicamento, porque tienen que eliminar muchas células malas rápidamente. A esas dosis, los efectos secundarios que describió su vecino son comunes: llagas, pérdida de peso, cambios en la piel. La policitemia vera que usted tiene no es un cáncer en ese sentido. Es una condición en la que la médula ósea produce demasiados glóbulos rojos — la fábrica trabaja de más. La hidroxiurea en su caso se usa en dosis mucho más bajas — probablemente una décima parte de lo que necesitó su vecino — para decirle a la médula que produzca menos. No estamos destruyendo células cancerosas. Estamos regulando una producción que se salió de control.”

Heriberto was listening. “¿Pero entonces por qué no me dieron los efectos secundarios que tuvo Óscar?”

“Exactamente por eso. A la dosis que usted estaba tomando — 500 miligramos dos veces al día — los efectos secundarios serios que tuvo su vecino generalmente no ocurren. Usted estuvo cuatro meses tomando el medicamento y nos dijo que se sentía bien. Eso era el medicamento funcionando, sin dañarlo. Y sus números lo confirmaban: el hematocrito a 43 y las plaquetas a 340,000 son los números que buscamos.”

She showed him the comparison on her tablet: his labs from four months ago (hematocrit 43%, platelets 340,000) against that morning’s result (hematocrit 54%, platelets 680,000).

“En diez semanas sin el medicamento, su hematocrito subió once puntos y las plaquetas se duplicaron. Eso es la médula volviendo a producir de más, porque el medicamento que la regulaba ya no está.”

“¿Y eso por qué es malo? Me siento bien.”

“El problema de la policitemia vera no es cómo se siente ahora — es lo que puede pasar después sin previo aviso. Cuando la sangre tiene demasiados glóbulos rojos y demasiadas plaquetas, se vuelve más espesa y tiene más tendencia a formar un coágulo en el lugar equivocado. El mayor riesgo de la policitemia vera no controlada es un infarto al corazón o un derrame cerebral que ocurre sin que haya habido ningún síntoma antes. Puede pasar a un hematocrito de 50 igual que a uno de 60. Con un hematocrito de 54 y 680,000 plaquetas, ese riesgo es real y está presente hoy.”

Heriberto was quiet for a moment. “¿O sea que el riesgo de seguir sin el medicamento es un infarto o un derrame?”

“Sí. No es seguro. No es un riesgo pequeño y remoto — es el riesgo principal de esta condición. Lo que su vecino le contó sobre la hidroxiurea era verdad para su situación. No es verdad para la suya. Su vecino necesitaba dosis de quimioterapia para tratar un cáncer. Usted necesita una décima parte de esa dosis para decirle a la médula que trabaje normal.”

Heriberto agreed to restart the hydroxyurea. The hematologist also ordered a therapeutic phlebotomy that afternoon to bring the hematocrit down more quickly. At his eight-week follow-up, his hematocrit was 46% and his platelet count was 410,000. At sixteen weeks, both were within target range.

When the nurse asked him how he was feeling about the medication now, Heriberto said: “Óscar me quería advertir — eso lo entiendo. Solo que lo que a él le pasó y lo que yo tengo no era lo mismo. Si hubiera sabido eso antes, no lo habría dejado.”

The patient with hemophilia whose infusion schedule is slipping because the pharmacy co-pay increased when he aged off his parents’ insurance

Marco Herrera had been on prophylactic factor VIII three times weekly since age fifteen — Advate, 30 IU/kg, Monday/Wednesday/Friday — and had not had a documented joint bleed in two consecutive years. His target joint, a left ankle that had bled repeatedly between ages ten and fourteen, had been stable on full prophylaxis since his first year on the three-times-weekly schedule. His annual bleed rate at his last evaluation: zero.

He turned twenty-six in January. He lost coverage under his parents’ plan on his birthday and enrolled in his employer’s insurance at work — a stockroom associate position at a food distribution company in San Antonio, $16.50 an hour, thirty hours a week. The plan had a specialty drug tier with a 10% co-pay, no cap on specialty medications. His factor VIII concentrate, at the prophylactic dose, cost $14,800 for a three-month supply through the specialty pharmacy. His 10% co-pay: $1,480 per quarter, or roughly $493 per month. The manufacturer co-pay assistance card — which would have reduced his out-of-pocket to $0 for commercial insurance — existed, but no one at the specialty pharmacy had mentioned it and he had not known to ask.

He had called the specialty pharmacy after he saw the first invoice. They had told him the co-pay was correct per his plan. They had not mentioned the manufacturer program. He had paid the first invoice, which was $480 after he had applied a $15 copay card he found searching online. The second invoice had arrived when the card ran out. He had paid $240 — all he had available — and stretched the supply by infusing twice a week instead of three times.

He was six weeks into the twice-weekly schedule. He had not had any acute bleeds. He arrived for his regular follow-up saying “todo está bien.”

The nurse had reviewed his order history before entering the room. His last three-month factor VIII order had been placed four months ago. The math did not add up for a three-times-weekly schedule.

She did not ask about bleeds first. She asked about the schedule.

“¿Cómo va el horario de las infusiones en casa — lunes, miércoles, viernes como siempre, o ha habido alguna semana donde salió diferente?”

Marco: “Más o menos. A veces cambian los días.”

“Veo que el último pedido de tres meses lo hicimos hace cuatro meses. ¿Le queda suficiente, o está llevando el suministro un poco justo?”

A pause. “La verdad, estoy haciéndolo dos veces por semana últimamente. No he tenido sangrado. El tobillo está bien.”

“Gracias por decirme. Cuando el horario cambia así, muchas veces hay algo práctico detrás. ¿Cambió algo en el seguro cuando empezó el trabajo nuevo?”

Marco: “El copago. Antes no pagaba nada — estaba en el plan de mis papás. Ahora me llegan como 480, 490 dólares por tres meses, y no tengo ese dinero todos los meses.”

The nurse wrote this down carefully. Then:

“Hay algo que probablemente nadie le mencionó en la farmacia: el fabricante del factor VIII que usted usa tiene un programa de asistencia al paciente que cubre el copago para personas con seguro comercial como el suyo. No es un descuento pequeño — en muchos casos cubre el copago completo y el costo del bolsillo se va a cero. La farmacia especial no está obligada a decirle esto, y muchas veces no lo hacen. Puedo conectarle con la trabajadora social del centro de hemofilia hoy mismo para que lo enrolen antes de que salga de aquí.”

Marco: “¿Eso existe?”

“Sí. Y se aplica retroactivamente a los dos últimos cobros en la mayoría de los programas — le pueden devolver parte de lo que ya pagó.”

She also explained why the three-times-weekly schedule was not arbitrary.

“La razón por la que hacemos las infusiones tres veces por semana no es solo para evitar un sangrado activo que usted siente. Es para mantener el nivel de factor VIII en su sangre por encima de un nivel mínimo todos los días. Su nivel de factor en condiciones normales es menos del uno por ciento. Con la profilaxis tres veces por semana, el nivel sube después de cada infusión y baja antes de la siguiente — pero el punto más bajo todavía está por encima del umbral donde los sangrados espontáneos ocurren. Con dos veces por semana, ese punto más bajo probablemente está cayendo por debajo de ese umbral antes de la siguiente dosis. El tobillo no le duele. Pero los sangrados pequeños que ocurren en una articulación cuando el nivel de factor está bajo no siempre duelen. Se acumulan. Son los que dan lugar a la artropatía hemófilica con el tiempo — el daño que los pacientes ven a los cuarenta años y que se empezó a construir a los veintiséis.”

Marco: “O sea que puede haber sangrado que no siento.”

“Exactamente. La profilaxis existe para evitar esos sangrados silenciosos. No para tratar el sangrado que ya pasó y que usted notó — para evitar el que está ocurriendo sin anunciarse. Seis semanas a dos infusiones por semana probablemente no ha causado daño visible todavía. Pero esto no puede continuar.”

The hemophilia treatment center social worker enrolled Marco in the manufacturer assistance program that afternoon. His co-pay for the next refill: $0. The program had a retroactive provision; after filing two invoices, he received a reimbursement of $720 for his prior out-of-pocket payments.

The nurse also submitted a referral for a joint MRI of his left ankle to establish a current baseline image, given the six weeks of altered prophylaxis, and flagged his trough factor VIII level for measurement at his next visit to verify that the three-times-weekly schedule was producing adequate trough levels for his current weight.

At the three-month follow-up, Marco had returned to his full three-times-weekly schedule. Annual bleed rate still zero. Ankle MRI: no new synovial changes, stable compared to the previous study from twenty-three months prior. “Nadie me había dicho que eso existía — el programa del fabricante. Pensé que el copago era el copago y ya.”

The three questions for every hematology clinic visit with a Spanish-speaking patient

The three encounters above are patterns. The sickle cell patient who is navigating employment with a condition she has not disclosed — who called in sick from the ED parking lot and called it a virus because she had no other language for it — is in every hematology clinic with a working-age sickle cell population. The polycythemia vera patient who stopped his medication after a neighbor’s warning is in every clinic where patients have social networks that include cancer survivors, which is every clinic. The hemophilia patient who has been rationing his prophylaxis for six weeks without mentioning it because he did not know the solution existed is in every hemophilia clinic that sees patients who recently changed insurance.

Three questions that find them:

“¿Ha habido algún día o semana en el último mes en que el trabajo, el horario, o algo que cambió en el seguro hiciera más difícil seguir el plan del medicamento tal como está planeado?”

This question does not ask whether the patient missed doses. It asks whether the conditions made adherence harder — a factual question about circumstances rather than a confession about behavior. It names the specific circumstances that most commonly drive non-adherence in hematology: work, schedule, and insurance. Naming them signals that the nurse already knows these things happen, which reduces the shame associated with reporting them. Valentina’s answer to the standard “¿cómo ha estado?” was “todo bien.” Her answer to a question about the work situation produced a conversation about the ED visit she had been carrying for three weeks. Marco’s answer to “todo bien?” was “todo está bien.” The schedule question, combined with the observation that his supply math did not add up, produced the co-pay disclosure that connected him to $1,200 in retroactive reimbursements and a restored prophylaxis schedule.

“¿Alguien cercano a usted — un familiar, un vecino, un amigo — ha tenido algo parecido a lo que usted tiene, o ha tomado alguno de los medicamentos que usted toma?”

The patient who stopped a medication because of what someone else experienced with the same drug has almost never told anyone about the connection, because he does not think the nurse will consider a neighbor’s cancer treatment relevant to his blood condition. This question names the phenomenon before the patient has to volunteer it. The word “cercano” — close to you — casts a wide net: family, neighbors, friends, the compadre who sat on the porch. The specific mention of “alguno de los medicamentos que usted toma” — any of the medications you take — is the phrase that gave Heriberto the opening to say what Óscar had told him. Without that opening, he would have said “bien, no tuve problemas” and the hematologist would have assumed his hematocrit of 54% was a failure of the medication, not a consequence of stopping it.

“¿Cómo va el horario de las infusiones en casa — tres veces por semana como siempre, o ha habido alguna semana donde salió diferente?”

This question asks about the schedule, not about bleeding. The outcome question — “¿ha tenido algún sangrado?” — does not find the patient who is rationing his prophylaxis, because the problem is not yet a bleed; it is the progressive depletion of the safety margin that will produce a bleed months from now. A patient on prophylaxis for eleven years with an annual bleed rate of zero has organized his sense of being well around not bleeding. He does not connect the twice-weekly schedule to a current clinical problem because there is no current clinical problem he can see. The schedule question asks about the practice, not the outcome, and the phrase “alguna semana donde salió diferente” normalizes the variation before he has to admit it as a failure. Marco’s answer — “más o menos” — was the beginning. The follow-up about the supply math closed it.

The practice at ClinicaLingo covers these and similar conversations across thirty clinic and ED encounters. The post on medication reconciliation in Spanish covers the systematic approach to finding what the patient stopped, why, and when — including the phrasing that distinguishes intentional discontinuation from missed doses from cost-driven rationing. The post on how to explain a diagnosis in Spanish covers the mechanism-first framing for chronic conditions that cause damage the patient cannot feel, which applies directly to the polycythemia vera conversation about thrombosis risk. The post on Spanish for oncology nurses covers the conversations that arise when patients conflate different types of cancer treatment — including why a patient’s prior experience with a relative’s cancer shapes how they understand their own diagnosis. The post on Spanish for rheumatology clinic nurses covers the patterns of biologic discontinuation for cost and social reasons in outpatient specialty settings.

The 50-phrase PDF covers the intake, pain scale, allergy, and discharge vocabulary most nurses need most often on most shifts. The hematology clinic posts cover the patterns that only appear at specific visit types — the sickle cell patient who has been navigating employment without accommodation language, the polycythemia patient who absorbed someone else’s cancer experience and applied it to his own treatment, and the hemophilia patient whose infusion schedule eroded quietly when his insurance changed and no one mentioned the program that would have prevented it.

These are not edge cases. The patient with a chronic blood disorder who has not told her employer because she does not know she has options is in every hematology clinic with a working-age population. The patient who stopped his medication after a neighbor’s warning is in every clinic where patients have social networks — which is every clinic. The patient who is rationing an expensive prophylactic agent because he did not know a manufacturer assistance program existed is in every specialty infusion setting where patients change insurance. What finds them is almost always a question that does not ask for a confession, that names the structural barrier before the patient has to volunteer it, and that opens the door wide enough for the truth to fit through.